| Bid | 28.25 |
| Market Cap | 4.61B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 2.29 |
| PE Ratio (ttm) | 12.45 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 45.31 |
| Volume | 790,275 |
| Avg. Volume (20D) | 1,639,693 |
| Open | 28.40 |
| Previous Close | 28.35 |
| Day's Range | 28.40 - 28.76 |
| 52-Week Range | 22.90 - 32.88 |
| Beta | undefined |
About ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the tre...
Analyst Forecast
According to 11 analyst ratings, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is $36.5, which is an increase of 28.05% from the latest price.
Next Earnings Release
Analysts project revenue of $380.74M, reflecting a 0.86% YoY growth and earnings per share of 0.75, making a 56.25% increase YoY.
1 month ago · seekingalpha.com
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term GrowthAlkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy...
